ALDH+ Cancer Precursor Cells in Drug Response Prediction
.
Mr. Ed Field, Chief Operating Officer at Aldagen, explains the principles behind ALDEFLUOR™-based detection of ALDH bright cells and discusses evidence demonstrating ALDH’s potential as a biomarker for cancer stem cell characterization and tumor prognosis.
Publish Date:
June 25, 2015
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
How to Detect and Isolate Normal and Cancer Stem Cells Based on ALDH Activity with ALDEFLUOR™
Publish Date: September 09, 2009 -
Flow Cytometry Analysis of ALDH Bright Cells with the ALDEFLUOR™ Assay Kit
Publish Date: September 06, 2011 -
Potential Applications of ALDH Bright Cells In Regenerative Medicine
Publish Date: May 27, 2011
Explore Our Products
-
Additional assay buffer for use with the ALDEFLUOR™ kit -
For the identification, evaluation, and isolation of stem and progenitor cells expressing high levels of ALDH -
ALDH enzyme inhibitor used as a control in the ALDEFLUOR™ assay system
